ArgenX Empassion
The Empassion study is designed to assess how safe and effective an investigational study drug, empasiprubart, is compared to intravenous immunoglobulin (IVIg) as a possible treatment for adults living with multifocal motor neuropathy (MMN).
The clinical study is looking to enroll up to 100 participants across the world. Enrolled participants will be asked to remain in the study for up to 49 months (nearly 4 years). This will include up to 15 weeks of screening, a 24-week treatment period (Part A), a 24-month open-label extension (Part B), and a 15-month safety follow-up period.
Inclusion Criteria:
· Are at least 18 years old.
· Are diagnosed with definite or probable MMN at screening.
· Are receiving a maintenance regimen (no change in frequency and no change in dose >10%) of IVIg for at least 8 weeks before screening, (or at least 10 weeks for participants receiving IVIg once every 5 weeks).
· Meet other criteria that the study staff will discuss with you.
